Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 January 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Toxins produced by C difficile effect disease severity

Research in this week's Lancet shows that the severity of C difficile-associated disease caused by polymerase chain reaction-ribotype 027 could result from hyperproduction of toxins A and B.

News image

fiogf49gjkf04

Toxins A and B are the primary virulence factors of Clostridium difficile.

Since 2002, an epidemic of C difficile-associated disease with increased morbidity and mortality has been present in Quebec province, Canada.

Dr Michel Warny and colleagues characterized the dominant strain of this epidemic.

The researchers determined whether the dominant strain produces higher amounts of toxins A and B than those produced by non-epidemic strains.

The research team obtained isolates from 124 patients from Centre Hospitalier Universitaire de Sherbrooke in Quebec.

Additional isolates from the USA, Canada, and the United Kingdom were included to increase the genetic diversity of the toxinotypes tested.

The epidemic strain was isolated from 72 with C difficile-associated disease
The Lancet

Isolate characterization included toxinotyping, pulsed-field gel electrophoresis, and polymerase chain reaction ribotyping.

The isolate characterization also included the detection of a binary toxin gene, and detection of deletions in a putative negative regulator for toxins A and B.

By use of an enzyme-linked immunoassay, the team measured the in-vitro production of toxins A and B by epidemic strain and non-dominant strain isolates.

The team found that the epidemic strain was characterized as toxinotype III, and North American pulsed-field gel electrophoresis type 1.

The polymerase chain reaction-ribotype 027 was also characterized by the epidemic strain.

The researchers noted that this strain carried the binary toxin gene cdtB and an 18-bp deletion in a putative negative regulator for toxins A and B.

The research team isolated this strain from 72 patients with C difficile-associated disease.

Peak median toxin A concentrations produced in vitro by polymerase chain reaction-ribotype 027 were 16 times higher than those measured in isolates.

The team observed that peak median toxin B concentrations produced in vitro by polymerase chain reaction-ribotype 027 were 23 times higher than those measured in isolates.

The isolates represented 12 different pulsed-field gel electrophoresis types, known as toxinotype 0.

Dr Warny's team concludes, “The severity of C difficile-associated disease caused by polymerase chain reaction-ribotype 027 could result from hyperproduction of toxins A and B.”

“Dissemination of this strain in North America and Europe could lead to important changes in the epidemiology of C difficile-associated disease.”

Lancet 2005: 366(9491):1079-84
27 September 2005

Go to top of page Email this page Email this page to a colleague

 17 January 2017 
Pediatric-onset Crohn's disease
 17 January 2017 
Biologic drugs and extraintestinal manifestations in IBD
 17 January 2017 
Colorectal cancer prevention among Medicare beneficiaries
 16 January 2017 
HCV eradication in cirrhosis
 16 January 2017 
Thyroid and primary biliary cholangitis
 16 January 2017 
Sarcopenia and severe liver fibrosis
 13 January 2017 
Early monocytopenia in paracetamol-induced liver failure
 13 January 2017 
Anti-TNF discontinuation in patients with IBD
 13 January 2017 
Isolated colonic Crohn's disease
 12 January 2017 
Providing relief for chronic constipation
 12 January 2017 
Internet-delivered therapy for adolescents with IBS
 12 January 2017 
NAFLD and coronary artery calcium score
 11 January 2017 
Fatigue in IBD
 11 January 2017 
Pancreatic cancer risk with asthma and nasal allergies
 11 January 2017 
PPIs and bone strength and structure
 10 January 2017 
Colorectal cancer risk in serrated polyposis syndrome
 10 January 2017 
Evaluation of abnormal liver chemistries
 10 January 2017 
Pelvic physiotherapy in functional constipation
 09 January 2017 
Intestinal microbiota and IBS
 09 January 2017 
Helicobacter and Campylobacter in IBD
 09 January 2017 
Diagnosis of microscopic colitis
 06 January 2017 
Recommendations on colorectal cancer screening 
 06 January 2017 
Colorectal cancer susceptibility gene variants
 06 January 2017 
Thiopurine-induced hepatotoxicity in IBD
 05 January 2017 
Histological index for ulcerative colitis
 05 January 2017 
Crohn's disease after total colectomy with permanent ileostomy
 05 January 2017 
Celiac disease screening in IBS
 04 January 2017 
Serrated colorectal polyps risk factors
 04 January 2017 
Score to predict eosinophilic esophagitis
 04 January 2017 
Platelet transfusion for gastrointestinal bleeding
 03 January 2017 
Pelvic physiotherapy for functional constipation in children
 03 January 2017 
Tumor necrosis factor antagonists in IBD
 03 January 2017 
Mesenchymal stromal cell therapy for IBD
 22 December 2016 
Happy holidays!
 21 December 2016 
Pharmacotherapy for NAFLD
 21 December 2016 
Predicting disease activity in eosinophilic esophagitis
 21 December 2016 
Breath Testing for Barrett’s esophagus
 20 December 2016 
H. pylori on the ethnic distribution of Barrett's metaplasia
 20 December 2016 
Prognostic biomarker in colorectal cancer
 20 December 2016 
Online health information for colorectal cancer screening
 19 December 2016 
Risk of tuberculosis in IBD
 19 December 2016 
Hospital research and colorectal cancer survival
 19 December 2016 
Risk of complications of percutaneous liver biopsy
 16 December 2016 
Mortality rates for major causes of death
 16 December 2016 
Predicting organ failure in acute pancreatitis
 16 December 2016 
Non-invasive genomic biomarkers for colorectal cancer
 15 December 2016 
Adjuvant chemotherapy use varies for advance colon cancer
 15 December 2016 
Histological index for ulcerative colitis
 15 December 2016 
Readmission after acute upper GI bleed
 14 December 2016 
Management of H. pylori infection
 14 December 2016 
Fecal microbiota transfer
 14 December 2016 
Colorectal cancer screening in primary care
 13 December 2016 
Caffeine and hepatitis C virus infection
 13 December 2016 
Features of asymptomatic erosive esophagitis
 13 December 2016 
Clinical relapse among patients with ulcerative colitis
 12 December 2016 
Colorectal cancer prevention
 12 December 2016 
Precision medicine in IBD
 12 December 2016 
Drug-induced liver injury 
 09 December 2016 
Use of GI alarm features for colorectal cancer diagnosis
 09 December 2016 
Emergency department use by IBD patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us